QUESTION: Does the administration of a specific pharmacologic agent (eg, methylprednisolone) improve clinical outcomes in patients with thoracic and lumbar fractures and spinal cord injury? RECOMMENDATION: There is insufficient evidence to make a recommendation; however, the task force concluded, in light of previously published data and guidelines, that the complication profile should be carefully considered when deciding on the administration of methylprednisolone. Strength of recommendation: Grade Insufficient The full version of the guideline can be reviewed at: https://www.cns.org/guidelinechapters/congress-neurological-surgeons-systematic-review-evidence-based-guidelines/ chapter_5. 
Goals and Rationale
There are currently few options available for the treatment of spinal cord injury (SCI). Surgical management includes decompression of the injured spinal cord and fixation and fusion of the spine with prevention of secondary injury, but surgery does not directly address the initial insult. Improvements in the medical management of SCI patients now provide the opportunity for a near-normal life span.
An increased understanding of the pathophysiology of SCI has led to the initiation of several recent pharmacologic clinical trials, including National Acute Spinal Cord Injury Study (NASCIS) I and II, the Sygen (GM-1 ganglioside) trials, riluzole, minocycline, and others. However, to date, none of these drugs ABBREVIATIONS: AANS, American Association of Neurological Surgeons; CNS, Congress of Neurological Surgeons; MPSS, methylprednisolone sodium succinate; NASCIS, National Acute Spinal Cord Injury Study; SCI, spinal cord injury have been shown to significantly improve neurological outcome following acute SCI, and the use of methylprednisolone for SCI remains controversial.
METHODS
Details of the systematic literature review are provided in the full text of this guideline (https://www. cns.org/guideline-chapters/congress-neurologicalsurgeons-systematic-review-evidence-based-guidelines/ chapter_5) and in the methodology (https://www. cns.org/guideline-chapters/congress-neurologicalsurgeons-systematic-review-evidence-based-guidelines/ chapter_1) article of this guideline series. The guidelines task force initiated a systematic review of the literature relevant to the diagnosis and treatment of patients with thoracolumbar SCIs. Through objective evaluation of the evidence and transparency in the process of making recommendations, this evidencebased clinical practice guideline was developed for the diagnosis and treatment of adult patients with thoracolumbar injury. These guidelines are developed for educational purposes to assist practitioners in their clinical decision-making processes.
PHARMACOLOGICAL TREATMENT
Additional information about the methods used in this systematic review can be found in the introduction and methodology chapter (https://www.cns.org/guideline-chapters/congress-neurologicalsurgeons-systematic-review-evidence-based-guidelines/chapter_1).
RESULTS
The literature search yielded 2614 abstracts. Task force members reviewed all abstracts yielded from the literature search and identified the literature for full text review and extraction, addressing the clinical questions, in accordance with the Literature Search Protocol (Appendix I; https://www.cns.org/ guideline-chapters/congress-neurological-surgeons-systematicreview-evidence-based-guidelines/chapter_5).
Task force members identified the best research evidence available to answer the targeted clinical questions. When Level I, II, or III literature was available to answer specific questions, the task force did not review Level IV studies.
The task force selected 167 articles for full text review. Of these, all studies were rejected for not meeting inclusion criteria or for being off-topic. No studies were selected for systematic review (Appendix II; https://www.cns.org/guideline-chapters/ congress-neurological-surgeons-systematic-review-evidence-basedguidelines/chapter_5).
DISCUSSION Methylprednisolone Sodium Succinate
Methylprednisolone sodium succinate (MPSS) is by far the most extensively studied pharmacologic agent used to treat patients with acute SCI. There have been 3 NASCIS studies performed between 1980 and 1998. The first study (NASCIS I) compared low-dose MPSS vs high-dose MPSS, and the short-and long-term results showed no significant neurological difference between the 2 groups. There were significantly more complications in the high-dose group, including a 3-times higher rate of wound infection. 1 The second NASCIS study (NASCIS II) compared a higher dose MPSS with naloxone and a placebo control. 2 The last NASCIS study (NASCIS III) compared a 24-h continuous infusion of MPSS vs a 48-h infusion. A third arm of the study looked at tirilizad mesylate. This trial showed no long-lasting neurological benefit of MPSS.
One other prospective study looked at the effects of MPSS for acute SCI. Pointillart et al 3 showed no benefit of MPSS. This study had a small number of patients and methodological flaws, and thus the value of these data is limited.
The use of MPSS as an adjunct to the management of acute SCI remains controversial, because of the paucity of functional neurological benefits, the high rate of complications in the MPSS group, and the use of post-hoc analysis to determine benefits in a subsection of the patient population. The American Association of Neurological Surgeons (AANS)/CNS Guidelines for the Management of Acute Cervical Spine and Spinal Cord Injuries (https://academic.oup.com/neurosurgery/article/72/suppl_3/54/ 2557454) were specific, noting that the use of MPSS was not recommended for the treatment of acute SCI. 4 The authors went on to note that the US Food and Drug Administration does not approve its use for SCI, and that there was no Class I or Class II medical evidence supporting MPSS for this diagnosis. They also noted the higher rate of complications, including death, associated with MPSS.
GM-1 Ganglioside (Sygen)
There have been 2 prospective randomized clinical trials that investigated the efficacy of Sygen, a GM-1 ganglioside, in the treatment of acute SCI. The first study was performed at a single institution with 37 patients. 5 Data showed that the GM-1 patients had significant neurological recovery compared to the MPSS-only patients, which was the impetus for a larger multicenter trial. However, this larger trial failed to show a significant difference in neurological outcome compared to the MPSS patients, despite a trend for earlier recovery in the GM-1 patients.
riluzole, 13 and granulocyte colony-stimulating factor 14 have also been investigated for use following traumatic SCI. These trials have been pilot studies, nonrandomized, or too underpowered to show any current benefit.
FUTURE RESEARCH
Despite intense interest and the completion of several welldesigned prospective randomized clinical trials, no pharmacologic agent has been shown to improve neurological outcomes in acute SCI. However, there are several current clinical trials investigating both pharmacologic and nonpharmacologic agents, and there is optimism that one of these therapies will be efficacious, offering hope for the treatment of this devastating injury. One of the current studies underway includes the In Vivo product, a scaffold that is placed intradurally in patients with American Spinal Injury Association thoracic SCI. Early results from this trial were encouraging, and data on the first 8 patients were presented at the CNS 2016 meeting in San Diego.
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CONCLUSION
For the past 30 yr, intense research has been focused on identifying an effective pharmacologic or cell-based treatment for patients with SCI. There have been significant advances at the molecular and preclinical levels in our understanding regarding the pathophysiology of SCI, but these advances have not translated to an effective treatment paradigm that will improve neurological outcome. Although several new potential therapies are currently under investigation, an effective treatment for acute SCI remains elusive.
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Disclaimer of Liability
This clinical systematic review and evidence-based guideline was developed by a multidisciplinary physician volunteer task force and serves as an educational tool designed to provide an accurate review of the subject matter covered. These guidelines are disseminated with the understanding that the recommendations by the authors and consultants who have collaborated in their development are not meant to replace the individualized care and treatment advice from a patient's physician(s). If medical advice or assistance is required, the services of a competent physician should be sought. The proposals contained in these guidelines may not be suitable for use in all circumstances. The choice to implement any particular recommendation contained in these guidelines must be made by a managing physician in light of the situation in each particular patient and on the basis of existing resources.
